Treatment of ocular disorders by gene therapy

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 331-342

  Solinís, M Ángeles ^a   Del Pozo Rodríguez, Ana ^a   Apaolaza, Paola S ^a   Rodríguez Gascón, Alicia ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Clinical trial; Cornea; Gene therapy; Non viral vector; Ocular disorder; Retina; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; NUCLEIC ACID; OLIGONUCLEOTIDE; POLYMER; RETROVIRUS VECTOR; SMALL INTERFERING RNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; AGE RELATED MACULAR DEGENERATION; ARTICLE; CHOROIDEREMIA; CLINICAL TRIAL (TOPIC); CORNEA DISEASE; CORNEA OPACITY; CORNEA TRANSPLANTATION; DIABETIC MACULAR EDEMA; EYE DISEASE; GENE EXPRESSION; GENE THERAPY; GLAUCOMA; HUMAN; IMMUNOGENICITY; LEBER CONGENITAL AMAUROSIS; MUTAGENESIS; NONHUMAN; NONVIRAL GENE THERAPY; PROMOTER REGION; RETINITIS PIGMENTOSA; RETINOSCHISIS; STARGARDT DISEASE; TARGET CELL; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; ANIMAL; EYE DISEASES; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETICS; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; EYE DISEASES; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84943815666     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.12.022     Document Type: Review

References (166)

1. B. Qin, R.S. Shukla, and K. Cheng Delivery of nucleic acids for ocular gene modulation A.K. Mitra, Advances in Ocular Drug Delivery 2012 Research Signpost Kerala India 87 114
2. P. Colella, G. Cotugno, and A. Auricchio Ocular gene therapy: current progress and future prospects Trends Mol. Med. 15 2009 23 31
3. C. Bloquel, J.L. Bourges, E. Touchard, M. Berdugo, D. BenEzra, and F. Behar-Cohen Non-viral ocular gene therapy: potential ocular therapeutic avenues Adv. Drug Deliver. Rev. 58 2006 1224 1242
4. A. Urtti Challenges and obstacles of ocular pharmacokinetics and drug delivery Adv. Drug Deliver. Rev. 58 2006 1131 1135
5. E.M. Del Amo, and A. Urtti Current and future ophthalmic drug delivery systems. A shift to the posterior segment Drug Discov. Today 13 2008 135 143
6. I.P. Kaur, and S. Kakkar Nanotherapy for posterior eye diseases J. Control. Release 2014 http://dx.doi.org/10.1016/j.jconrel.2014.05.031
7. A.C. Amrite, and U.B. Kompella Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration J. Pharm. Pharmacol. 57 2005 1555 1563
8. J.A. Guy, M.B. Sherwood, L. Balasubramanian, J.W. Doyle, M.F. Smith, G. van Setten, and et al. Enhanced short-term plasmid transfection of filtration surgery tissues Invest. Ophthalmol. Vis. Sci. 41 2000 4158 4162
9. K.S. Balaggan, K. Binley, M. Esapa, S. Iqball, Z. Askham, O. Kan, and et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors J. Gene Med. 8 2006 275 285
10. R. Gerometta, M.G. Spiga, T. Borrás, and O.A. Candia Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus Invest. Ophthalmol. Vis. Sci. 51 2010 3042 3048
11. I.D. Ladas, D.A. Karagiannis, A.A. Rouvas, A.I. Kotsolis, A. Liotsou, and I. Vergados Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections Retina 29 2009 313 318
12. S. Young, G. Larkin, M. Branley, and S. Lightman Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis Clin. Exp. Ophthalmol. 29 2001 2 6
13. J. Shen, R. Samul, R.L. Silva, H. Akiyama, H. Liu, Y. Saishin, and et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 Gene Ther. 13 2006 225 234
14. S.D. Nadine, W. Shanhong, S.B. Ottrina, J.K. Douglas, and S.J. Reich Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes Mol. Vis. 14 2008 997 1005
15. F. Testa, A.M. Maguire, S. Rossi, E.A. Pierce, P. Melillo, K. Marshall, and et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2 Ophthalmology 120 2013 1283 1291
16. J. Bennett, M. Ashtari, J. Wellman, K.A. Marshall, L.L. Cyckowski, D.C. Chung, and et al. AAV2 gene therapy readministration in three adults with congenital blindness Sci. Trans. Med. 4 2012 120ra15
17. U.B. Kompella, A.C. Amrite, R.R. Pacha, and S.A. Durazo Nanomedicines for back of the eye drug delivery, gene delivery, and imaging Prog. Retin. Eye Res. 36 2013 172 198
18. T.W. Olsen, X. Feng, K. Wabner, K. Csaky, S. Pambuccian, and J.D. Cameron Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model Invest. Ophthalmol. Vis. Sci. 52 2011 4749 4756
19. E. Touchard, M. Berdugo, P. Bigey, M. El Sanharawi, M. Savoldelli, M.C. Naud, and et al. Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina Mol. Ther. 20 2012 1559 1570
20. M.C. Peden, J. Min, C. Meyers, Z. Lukowski, Q. Li, S.L. Boye, and et al. Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter PLoS One 6 2011 e17140
21. S.M. Conley, and M.I. Naash Nanoparticles for retinal gene therapy Prog. Retin. Eye Res. 29 2010 376 397
22. The Journal of Gene Medicine Clinical Trial site. < http://www.abedia.com/wiley/indications.php > (last query: 08.09.14).
23. A. Guzman-Aranguez, P. Loma, and J. Pintor Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy Br. J. Pharmacol. 170 2013 730 747
24. K. Jooss, and N. Chirmule Immunity to adenovirus and adenoassociated viral vectors: implications for gene therapy Gene Ther. 10 2003 955 963
25. N. Bessis, F.J. Garcia Cozar, and M.C. Boissier Immune responses to gene therapy vectors: influence on vector function and effector mechanisms Gene Ther. 11 2004 S10 S17
26. N. Provost, G. Le Meur, M. Weber, A. Mendes-Madeira, G. Podevin, Y. Cherel, and et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain Mol. Ther. 11 2005 275 283
27. M.M. Liu, J. Tuo, and C.C. Chan Gene therapy for ocular diseases Br. J. Ophthalmol. 95 2011 604 612
28. R.R. Mohan, A. Sharma, M.V. Netto, S. Sinha, and S.E. Wilson Gene therapy in the cornea Prog. Retin. Eye Res. 24 2005 537 559
29. L. Jager, and A. Ehrhardt Emerging adenoviral vectors for stable correction of genetic disorders Curr. Gene Ther. 7 2007 272 283
30. M. Saghizadeh, A.A. Kramerov, F.S. Yu, M.G. Castro, and A.V. Ljubimov Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene Invest. Ophthalmol. Vis. Sci. 51 2010 1970 1980
31. R.M. Rajiv, J.C.K. Tovey, A. Sharma, and A. Tandon Gene therapy in the cornea: 2005-present Prog. Retin. Eye Res. 31 2012 43 64
32. N. Gong, U. Pleyer, H.D. Volk, and T. Ritter Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival Gene Ther. 14 2007 484 490
33. N. Gong, U. Pleyer, K. Vogt, I. Anegon, A. Flügel, H.D. Volk, and et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival Invest. Ophthalmol. Vis. Sci. 48 2007 1043 1052
34. B.T. Gabelt, Y. Hu, J.L. Vittitow, C.R. Rasmussen, I. Grosheva, A.D. Bershadsky, and et al. Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments Exp. Eye Res. 82 2006 935 944
35. M.G. Spiga, and T. Borrás Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma Invest. Ophthalmol. Vis. Sci. 51 2010 3029 3041
36. Y. Chen, G. Moiseyev, Y. Takahashi, and J.X. Ma RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice Invest. Ophthalmol. Vis. Sci. 47 2006 1177 1184
37. P.A. Campochiaro, Q.D. Nguyen, S.M. Shah, M.L. Klein, E. Holz, R.N. Frank, and et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial Hum. Gene Ther. 17 2006 167 176
38. M.S. Cashman, K. Ramo, and R. Kumar-Singh A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration PLoS One 6 2011 e19078
39. S. Lamartina, M. Cimino, G. Roscilli, E. Dammassa, D. Lazzaro, R. Rota, and et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy J. Gene Med. 9 2007 862 874
40. F. Meng, X. Wang, P. Gu, Z. Wang, and W. Guo Induction of retinal ganglion-like cells from fibroblasts by adenoviral gene delivery Neuroscience 250 2013 381 393
41. V.M. Rivera, G.P. Gao, R.L. Grant, M.A. Schnell, P.W. Zoltick, L.W. Rozamus, and et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer Blood 105 2005 1424 1430
42. M.S. Enrico, and A. Auricchio Versatility of AAV vectors for retinal gene transfer Vis. Res. 48 2008 353 359
43. R.R. Ali, M.B. Reichel, M. de Alwis, N. Kanuga, C. Kinnon, R.J. Levinsky, and et al. Adeno-associated virus gene transfer to mouse retina Hum. Gene Ther. 9 1998 81 86
44. J. Bennett, A.M. Maguire, A.V. Cideciyan, M. Schnell, E. Glover, V. Anand, and et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retin Proc. Natl. Acad. Sci. USA 96 1999 9920 9925
45. F.Q. Liang, T.S. Aleman, N.S. Dejneka, L. Dudus, K.J. Fisher, A.M. Maguire, and et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa Mol. Ther. 4 2001 461 472
46. S. Folliot, D. Briot, H. Conrath, N. Provost, Y. Cherel, P. Moullier, and et al. Sustained tetracycline-regulated transgene expression in vivo in rat ganglion cells using a single type 2 adeno-associated viral vector J. Gene Med. 5 2003 493 501
47. C. Mussolino, M. della Corte, S. Rossi, F. Viola, U. Di Vicino, E. Marrocco, and et al. AAV-mediated photoreceptor transduction of the pig cone-enriched retin Gene Ther. 18 2011 637 645
48. A. Manfredi, E. Marrocco, A. Puppo, G. Cesi, A. Sommella, M. Della Corte, and et al. Combined rod and cone transduction by adeno-associated virus 2/8 Hum. Gene Ther. 24 2013 982 992
49. S.H. Min, L.L. Molday, M.W. Seeliger, A. Dinculescu, A.M. Timmers, A. Janssen, and et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis Mol. Ther. 12 2005 644 651
50. A. Janssen, S.H. Min, L.L. Molday, N. Tanimoto, M.W. Seeliger, W.W. Hauswirth, and et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin deficient mouse Mol. Ther. 16 2008 1010 1017
51. T.K. Park, Z. Wu, S. Kjellstrom, Y. Zeng, R.A. Bush, P.A. Sieving, and et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse Gene Ther. 16 2009 916 926
52. D. Dalkara, L.C. Byrne, R.R. Klimczak, M. Visel, L. Yin, W.H. Merigan, and et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous Sci. Trans. Med. 5 2013 189ra76
53. L.C. Byrne, B.E. Öztürki, T. Lee, C. Fortuny, M. Visel, D. Dalkara, and et al. Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h-/- mouse Gene Ther. 21 2014 585 592
54. A. Sharma, A. Ghosh, E.T. Hansen, J.M. Newman, and R.R. Mohan Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts Brain Res. Bull. 81 2010 273 278
55. A. Sharma, J.C. Tovey, A. Ghosh, and R.R. Mohan AAV serotype influences gene transfer in corneal stroma in vivo Exp. Eye Res. 91 2010 440 448
56. L. Zhong, B. Li, C.S. Mah, L. Govindasamy, M. Agbandje-McKenna, M. Cooper, and et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses Proc. Natl. Acad. Sci. USA 105 2008 7827 7832
57. W.T. Deng, A. Dinculescu, Q. Li, S.L. Boye, J. Li, M.S. Gorbatyuk, and et al. Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats Invest. Ophthalmol. Vis. Sci. 53 2012 1895 1904
58. C.N. Kay, R.C. Ryals, G.V. Aslanidi, S.H. Min, Q. Ruan, J. Sun, and et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors PLoS One 26 2013 e62097
59. F.M. Mowat, K.R. Gornik, A. Dinculescu, S.L. Boye, W.W. Hauswirth, S.M. Petersen-Jones, and et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach Gene Ther. 21 2014 96 105
60. K.S. Balaggan, and R.R. Ali Ocular gene delivery using lentiviral vectors Gene Ther. 19 2012 145 153
61. R.P. Molina, H.Q. Ye, J. Brady, J. Zhang, H. Zimmerman, M. Kaleko, and et al. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct Hum. Gene Ther. 15 2004 865 877
62. R. Berkowitz, H. Ilves, W.Y. Lin, E. Karl, A. Coward, S. Tamaki, and et al. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus J. Virol. 75 2001 3371 3382
63. R.J. Yanez-Munoz, K.S. Balaggan, A. MacNeil, S.J. Howe, M. Schmidt, A.J. Smith, and et al. Effective gene therapy with nonintegrating lentiviral vectors Nat. Med. 12 2006 348 353
64. K.A. Williams, and D.J. Coster Gene therapy for diseases of the cornea - a review Clin. Exp. Ophthalmol. 38 2010 93 103
65. D.G. Parker, C. Kaufmann, H.M. Brereton, D.S. Anson, L. Francis-Staite, C.F. Jessup, and et al. Lentivirus mediated gene transfer to the rat, ovine and human cornea Gene Ther. 14 2007 760 767
66. A.P. Bemelmans, C. Kostic, S.V. Crippa, W.W. Hauswirth, J. Lem, F.L. Munier, and et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis PLoS Med. 3 2006 e347
67. J. Kong, S.R. Kim, K. Binley, I. Pata, K. Doi, J. Mannik, and et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy Gene Ther. 15 2008 1311 1320
68. K. Binley, P. Widdowson, J. Loader, M. Kelleher, S. Iqball, G. Ferrige, and et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease Invest. Ophthalmol. Vis. Sci. 54 2013 4061 4071
69. M. Takahashi, H. Miyoshi, I.M. Verma, and F.H. Gage Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer J. Virol. 73 1999 7812 7816
70. K. Binley, P.S. Widdowson, M. Kelleher, J. de Belin, J. Loader, G. Ferrige, and et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration Hum. Gene Ther. 23 2012 980 991
71. H. Xu, J. Liu, S. Xiong, Y.Z. Le, and X. Xia Suppression of retinal neovascularization by lentivirus-mediated netrin-1 small hairpin RNA Ophthalmic Res. 47 2012 163 169
72. S. Hacein-Bey-Abina, A. Garrigue, G.P. Wang, J. Soulier, A. Lim, E. Morillon, and et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 J. Clin. Invest. 118 2008 3132 3142
73. R.W. Herzog Gene therapy for SCID-X1: round 2 Mol. Ther. 18 2010 1891
74. R. Naik, A. Mukhopadhyay, and M. Ganguli Gene delivery to the retina: focus on non-viral approaches Drug Discov. Today 14 2009 306 315
75. X. Cai, S. Conley, and M. Naash Nanoparticle applications in ocular gene therapy Vis. Res. 48 2008 319 324
76. A. Elouahabi, and J.M. Ruysschaert Formation and intracellular trafficking of lipoplexes and polyplexes Mol. Ther. 11 2005 336 347
77. A. Rodríguez-Gascón, A. del Pozo-Rodríguez, and M.A. Solinís Non-viral delivery systems in gene therapy F. Martín Molina, Gene Therapy - Tools and Potential Applications 2013 InTech Open Science Rijeka, Croatia 3 33
78. M. Mével, N. Kamaly, S. Carmona, M.H. Oliver, M.R. Jorgensen, C. Crowther, and et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA J. Control. Release 143 2010 222 232
79. A. Rodríguez-Gascón, A. del Pozo-Rodríguez, and M.Á. Solinís Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles Int. J. Nanomed. 9 2014 1833 1843
80. I. Masuda, T. Matsuo, T. Yasuda, and N. Matsuo Gene transfer with liposomes to the intraocular tissues by different routes of administration Invest. Ophthalmol. Vis. Sci. 37 1996 1914 1920
81. K. Abul-Hassan, R. Walmsley, and M. Boulton Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells Curr. Eye Res. 20 2000 361 366
82. E. Mannermaa, S. Rönkkö, M. Ruponen, M. Reinisalo, and A. Urtti Long-lasting secretion of transgene product from differentiated and filter-grown retinal pigment epithelial cells after nonviral gene transfer Curr. Eye Res. 30 2005 345 353
83. L. Peeters, N.N. Sanders, K. Braeckmans, K. Boussery, J. Van de Voorde, S.C. De Smedt, and et al. Vitreous: a barrier to nonviral ocular gene therapy Invest. Ophthalmol. Vis. Sci. 46 2005 3553 3561
84. C.W. Chen, M.K. Yeh, C.Y. Shiau, C.H. Chiang, and D.W. Lu Efficient downregulation of VEGF in retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery Int. J. Nanomed. 8 2013 2613 2627
85. A. del Pozo-Rodríguez, D. Delgado, A.R. Gascón, and M.Á. Solinís Lipid nanoparticles as drug/gene delivery systems to the retina J. Ocul. Pharmacol. Ther. 29 2013 173 188
86. A. del Pozo-Rodríguez, D. Delgado, M.A. Solinís, A.R. Gascón, and J.L. Pedraz Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells Int. J. Pharm. 360 2008 177 183
87. A. del Pozo-Rodríguez, S. Pujals, D. Delgado, M.A. Solinís, A.R. Gascón, E. Giralt, and et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors J. Control. Release 133 2009 52 59
88. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, and A. Rodríguez-Gascón Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway Eur. J. Pharm. Biopharm. 79 2011 495 502
89. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, M. Avilés-Triqueros, B.H. Weber, E. Fernández, and et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis Hum. Gene Ther. 23 2012 345 355
90. D. Delgado, A.R. Gascón, A. del Pozo-Rodríguez, E. Echevarría, A.P. Ruiz de Garibay, J.M. Rodríguez, and et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice Int. J. Pharm. 425 2012 35 43
91. D. Delgado, A. del Pozo-Rodríguez, M.A. Solinís, A. Bartkowiak, and A. Rodríguez-Gascón New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation Eur. J. Pharm. Sci. 50 2013 484 491
92. P.S. Apaolaza, D. Delgado, A. del Pozo-Rodríguez, A.R. Gascón, and M.A. Solinís A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Int. J. Pharm. 465 2014 413 426
93. W. Tiyaboonchai, J. Woiszwillo, and C.R. Middaugh Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles Eur. J. Pharm. Sci. 19 2003 191 202
94. A.L. Gomes dos Santos, A. Bochot, N. Tsapis, F. Artzner, R.A. Bejjani, B. Thillaye- Goldenberg, and et al. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy Pharm. Res. 23 2006 L.770 L.781
95. L. Pitkanen, M. Ruponen, J. Nieminen, and A. Urtti Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers Pharm. Res. 20 2003 576 583
96. C.N. Kuo, L.C. Yang, P.C. Wu, H.K. Kuo, C.J. Kuo, and M.H. Tai Dehydrated form of plasmid expressing basic fibroblast growth factor-polyethylenimine complex is a novel and accurate method for gene transfer to the cornea Curr. Eye Res. 30 2005 1015 1024
97. C.H. Peng, J.Y. Cherng, G.Y. Chiou, Y.C. Chen, C.H. Chien, C.L. Kao, and et al. Delivery of Oct4 and SirT1 with cationic polyurethanes-short branch PEI to aged retinal pigment epithelium Biomaterials 32 2011 9077 9088
98. M. Hornof, M. de la Fuente, M. Hallikainen, R.H. Tammi, and A. Urtti Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells J. Gene Med. 10 2008 70 80
99. T. Kurosaki, M. Uematsu, K. Shimoda, K. Suzuma, M. Nakai, T. Nakamura, and et al. Ocular gene delivery systems using ternary complexes of plasmid DNA, polyethylenimine, and anionic polymers Biol. Pharm. Bull. 36 2013 96 101
100. R.A. Bejjani, D. BenEzra, H. Cohen, J. Rieger, C. Andrieu, J.C. Jeanny, and et al. Nanoparticles for gene delivery to retinal pigment epithelial cells Mol. Vis. 11 2005 124 132
101. K.G. Carrasquillo, J.A. Ricker, I.K. Rigas, J.W. Miller, E.S. Gragoudas, and A.P. Adamis Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres Invest. Ophthalmol. Vis. Sci. 44 2003 290 299
102. O. Felt, P. Furrer, J.M. Mayer, B. Plazonnet, P. Buri, and R. Gurny Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention Int. J. Pharm. 180 1999 185 193
103. E.A. Klausner, Z. Zhang, S.P. Wong, R.L. Chapman, M.V. Volin, and R.P. Harbottle Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free, or S/MAR plasmid DNA J. Gene Med. 14 2011 100 108
104. M. de la Fuente, B. Seijo, and M.J. Alonso Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy Invest. Ophthalmol. Vis. Sci. 49 2008 2016 2024
105. L. Gan, J. Wang, Y. Zhao, D. Chen, C. Zhu, J. Liu, and et al. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection Biomaterials 34 2013 5978 5987
106. A. Arnedo, J.M. Irache, M. Merodio, and M.S. Espuelas Millán Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide J. Control. Release 94 2004 217 227
107. R.J. Marano, N. Wimmer, P.S. Kearns, B.G. Thomas, I. Toth, M. Brankov, and et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide Exp. Eye Res. 79 2004 525 535
108. M. Männistö, S. Vanderkerken, V. Toncheva, M. Elomaa, M. Ruponen, E. Schacht, and et al. Structure-activity relationships of poly(l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery J. Control. Release 83 2002 169 182
109. Y.C. Tong, S.F. Chang, C.Y. Liu, W.W. Kao, C.H. Huang, and J. Liaw Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters J. Gene Med. 9 2007 956 966
110. H.M. Prentice, M.R. Biswal, C.K. Dorey, and J.C. Blanks Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease Invest. Ophthalmol. Vis. Sci. 52 2011 8562 8570
111. A. Furukawa, C. Koike, P. Lippincott, C.L. Cepko, and T. Furukawa The mouse Crx 5′-upstream transgene sequence directs cell-specific and developmentally regulated expression in retinal photoreceptor cells J. Neurosci. 22 2002 1640 1647
112. S.C. Khani, B.S. Pawlyk, O.V. Bulgakov, E. Kasperek, J.E. Young, M. Adamian, and et al. AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter Invest. Ophthalmol. Vis. Sci. 48 2007 3954 3961
113. S.E. Boye, J.J. Alexander, S.L. Boye, C.D. Witherspoon, K.J. Sandefer, T.J. Conlon, and et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina Hum. Gene Ther. 23 2012 1101 1115
114. J.W. Bainbridge, A. Mistry, K. Binley, M. De Alwis, A.J. Thrasher, S. Naylor, and et al. Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization Gene Ther. 10 2003 1049 1054
115. G.A. Silva, D.C. Chung, J. Bennicelli, J. Bennett, Externally regulated AAV-mediated delivery of PEDF ameliorates the OIR phenotype, in: ARVO 2008 Annual Meeting: 2008 April 27-May 1, Association for Research in Vision and Ophthalmology Inc., Ft Lauderdale, FL, 2008.
116. D.G. Parker, H.M. Brereton, S. Klebe, D.J. Coster, and K.A. Williams A steroid-inducible promoter for the cornea Br. J. Ophthalmol. 93 2009 1255 1259
117. A. Koirala, R.S. Makkia, S.M. Conley, M.J. Cooper, and M.I. Naash S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA Hum. Mol. Genet. 22 2013 1632 1642
118. A. Koirala, S.M. Conley, and M.I. Naash Episomal maintenance of S/MAR-containing non-viral vectors for RPE-based diseases Adv. Exp. Med. Biol. 801 2014 703 709
119. P. Bettin, and F. Di Matteo Glaucoma: present challenges and future trends Ophthalmic Res. 50 2013 197 208
120. S. Alqawlaq, J.M. Sivak, H.J. Torin, M.V. Ivanova, J. Flanagan, M.A. Beazely, and et al. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy Nanomedicine 2014 10.1016/j.nano.2014.05.010
121. C. Bucolo, S. Salomone, F. Drago, M. Reibaldi, A. Longo, and M.G. Uva Pharmacological management of ocular hypertension: current approaches and future prospective Curr. Opin. Pharmacol. 13 2013 50 55
122. J. Moreno-Montañés, B. Sádaba, V. Ruz, A. Gómez-Guiu, J. Zarranz, M.V. González, and et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure Mol. Ther. 22 2014 226 232
123. S.K. Sikkink, S. Biswas, N.R. Parry, P.E. Stanga, and D. Trump X-linked retinoschisis: an update J. Med. Genet. 44 2007 225 232
124. A. Tantri, T.R. Vrabec, A. Cu-Unjieng, A. Frost, W.H. Annesley Jr., and L.A. Donoso X-linked retinoschisis: a clinical and molecular genetic review Surv. Ophthalmol. 49 2004 214 230
125. L.S. Kim, W. Seiple, G.A. Fishman, and J.P. Szlyk Multifocal ERG findings in carriers of X-linked retinoschisis Doc. Ophthalmol. 114 2007 21 26
126. R. Allikmets, N. Singh, H. Sun, N.F. Shroyer, A. Hutchinson, A. Chidambaram, and et al. A photoreceptor cellspecific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy Nat. Genet. 15 1997 236 246
127. F.P. Cremers, D.J. van de Pol, M. van Driel, A.I. den Hollander, F.J. van Haren, N.V. Knoers, and et al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in Stargardts disease ABCR Hum. Mol. Gen. 7 1998 355 362
128. A. Martinez-Mir, E. Paloma, R. Allikmets, C. Ayuso, T. del Rio, M. Dean, and et al. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease ABCR Nat. Genet. 18 1998 11 12
129. Y. Tsybovsky, R.S. Molday, and K. Palczewski The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease Adv. Exp. Med. Biol. 703 2010 105 125
130. Z. Han, S.M. Conley, and M.I. Naash Gene therapy for Stargardt disease associated with ABCA4 gene Adv. Exp. Med. Biol. 801 2014 719 724
131. Z. Han, S.M. Conley, R.S. Makkia, M.J. Cooper, and M.I. Naash DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice J. Clin. Invest. 122 2012 3221 3226
132. V. Kalatzis, C.P. Hamel, and I.M. MacDonald First international choroideremia research symposium, choroideremia: towards a therapy Am. J. Ophthalmol. 156 2013 433 437
133. N.V. Gordiyenko, R.N. Fariss, C. Zhi, and I.M. MacDonald Silencing of the CHM gene alters phagocytic and secretory pathways in the retinal pigment epithelium Invest. Ophthalmol. Vis. Sci. 51 2010 1143 1150
134. S.G. Jacobson, A.V. Cideciyan, A. Sumaroka, T.S. Aleman, S.B. Schwartz, E.A. Windsor, and et al. Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations Invest. Ophthalmol. Vis. Sci. 47 2006 4113 4120
135. P.A. Sieving, R.C. Caruso, W. Tao, H.R. Coleman, D.J. Thompson, K.R. Fullmer, and et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants Proc. Natl. Acad. Sci. USA 103 2006 3896 3901
136. R.E. MacLaren, M. Groppe, A.R. Barnard, C.L. Cottriall, T. Tolmachova, L. Seymour, and et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial Lancet 383 2014 1129 1137
137. H. Petrs-Silva, and R. Linden Advances in gene therapy technologies to treat retinitis pigmentosa Clin. Ophthalmol. 8 2014 127 136
138. C. Hamel Retinitis pigmentosa Orphanet. J. Rare Dis. 1 2006 40
139. W. Berger, B. Kloeckener-Gruissem, and J. Neidhardt The molecular basis of human retinal and vitreoretinal diseases Prog. Retin. Eye Res. 29 2010 335 375
140. S. Michalakis, S. Koch, V. Sothilingam, M.G. Garrido, N. Tanimoto, E. Schulze, and et al. Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa Adv. Exp. Med. Biol. 801 2014 733 739
141. E. Lhériteau, L. Petit, M. Weber, G. Le Meur, J.Y. Deschamps, L. Libeau, and et al. Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy Mol. Ther. 22 2014 265 277
142. S. Millington-Ward, B. O'Neill, G. Tuohy, N. Al-Jandal, A.S. Kiang, P.F. Kenna, and et al. Strategems in vitro for gene therapies directed to dominant mutations Hum. Mol. Genet. 6 1997 1415 1426
143. M. O'Reilly, A. Palfi, N. Chadderton, S. Millington-Ward, M. Ader, T. Cronin, and et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo Am. J. Hum. Genet. 81 2007 127 135
144. L.K. Cheung, and A. Eaton Age-related macular degeneration Pharmacotherapy 33 2013 838 855
145. A. Feret, S. Steinweg, H.C. Griffin, and S. Glover Macular degeneration: types, causes, and possible interventions Geriatr. Nurs. 28 2007 387 392
146. M. van Lookeren Campagne, J. LeCouter, B.L. Yaspan, and W. Ye Mechanisms of age-related macular degeneration and therapeutic opportunities J. Pathol. 232 2014 151 164
147. L.G. Fritsche, W. Chen, M. Schu, B.L. Yaspan, Y. Yu, G. Thorleifsson, and et al. Seven new loci associated with age-related macular degeneration Nat. Genet. 45 2013 433 439
148. K.D. Rittenhouse, T.R. Johnson, P. Vicini, B. Hirakawa, D. Kalabat, A.H. Yang, and et al. RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801 Invest. Ophthalmol. Vis. Sci. 55 2014 1232 1240
149. Q.D. Nguyen, R.A. Schachar, C.I. Nduaka, M. Sperling, A.S. Basile, K.J. Klamerus, and et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients Eye 26 2012 1099 1105
150. F.I. Al-Saikhan The gene therapy revolution in ophthalmology Saudi J. Ophthalmol. 27 2013 107 111
151. G. Thumann Prospectives for gene therapy of retinal degenerations Curr. Genomics 13 2012 350 362
152. R.W. Collin, A.I. den Hollander, S.D. van der Velde-Visser, J. Bennicelli, J. Bennett, and F.P. Cremers Antisense oligonucleotide (AON)-based therapy for Leber Congenital Amaurosis caused by a frequent mutation in CEP290 Mol. Ther. Nucl. Acids 27 2012 e14
153. E.R. Burnight, L.A. Wiley, A.V. Drack, T.A. Braun, K.R. Anfinson, E.E. Kaalberg, and et al. CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype Gene Ther. 2014 10.1038/gt.2014.39
154. J.W. Bainbridge, A.J. Smith, S.S. Barker, S. Robbie, R. Henderson, K. Balaggan, and et al. Effect of gene therapy on visual function in Leber's congenital amaurosis N. Engl. J. Med. 358 2008 2231 2239
155. E. Banin, D. Bandah-Rozenfeld, A. Obolensky, A.V. Cideciyan, T.S. Aleman, D. Marks-Ohana, and et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel Hum. Gene Ther. 21 2010 1749 1757
156. A.V. Cideciyan, T.S. Aleman, S.L. Boye, S.B. Schwartz, S. Kaushal, A.J. Roman, and et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics Proc. Natl. Acad. Sci. USA 105 2008 15112 15117
157. A.M. Maguire, F. Simonelli, E.A. Pierce, E.N. Pugh Jr., F. Mingozzi, J. Bennicelli, and et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis N. Engl. J. Med. 358 2008 2240 2248
158. A.V. Cideciyan, S.G. Jacobson, W.A. Beltran, A. Sumaroka, M. Swider, S. Iwabe, and et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement Proc. Natl. Acad. Sci. USA 110 2013 517 525
159. N. Serratrice, A. Cubizolle, S. Ibanes, N. Mestre-Francés, N. Bayo-Puxan, S. Creyssels, and et al. Corrective GUSB transfer to the canine mucopolysaccharidosis VII cornea using a helper-dependent canine adenovirus vector J. Control. Release 181 2014 22 31
160. H.M. Elbadawy, M. Gailledrat, C. Desseaux, D. Ponzin, and S. Ferrari Targeting herpetic keratitis by gene therapy J. Ophthalmol. 2012 2012 594869
161. J.S. Smith, and N.J. Robinson Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review J. Infect. Dis. 186 2002 S3 S28
162. H.M. Elbadawy, M. Gailledrat, C. Desseaux, G. Salvalaio, E. Di Iorio, B. Ferrari, and et al. Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo Gene Ther. 21 2014 272 281
163. Y. Qazi, and P. Hamrah Gene therapy in corneal transplantation Semin. Ophthalmol. 28 2013 287 300
164. X.L. Tang, J.F. Sun, X.Y. Wang, L.L. Du, and P. Liu Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds Mol. Vis. 16 2010 2354 2361
165. T. Ritter, J. Yang, H. Dannowski, K. Vogt, H.D. Volk, and U. Pleyer Effects of interleukin-12p40 gene transfer on rat corneal allograft survival Transpl. Immunol. 18 2007 101 107
166. D.G. Parker, D.J. Coster, H.M. Brereton, P.H. Hart, R. Koldej, D.S. Anson, and et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea Clin. Exp. Ophthalmol. 38 2010 405 413